Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$6.88 -0.82%

-$0.17 today

Market cap
$284.49M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.60M

Average 0.38M

EVMN Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Evommune, Inc.NYSE: EVMN

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 300.0% from a year ago

Common stock stood at $4K at the end of Q1 FY2026, up 300.0% from a year earlier and up 33.3% from the prior quarter.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 1 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +300.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4K+33.3% QoQ
Last fiscal yearDec 2025
$3K+200.0% YoY
Year agoMar 2025
$1K+300.0% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+300.0%——
1 year+200.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
3K USD
Year-over-year change
+200.0%
2-year CAGR
+73.2%

Common Stock vs competitors

How EVMN compares with its peers on the latest reported figures

  • EVMN's Mar 2026 common stock of $4K is the 9th highest of the 10 companies compared; the peer median is $14K.
  • Its year-over-year change of +300.0% is the highest of 10, against a peer median of +4.2%.
  • Common stock amounts to 0.0% of total assets for EVMN, versus a peer median of 0.0%.
EVMN Competitors Peer median
Common Stock for EVMN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZYMEZymeworks Inc.Sep 2026$1.15B +4.2%+7.1%97.5%
FTREFortrea Holdings Inc.Jun 2026$100K +0.0%—0.0%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$83K +20.3%+34.6%0.0%
LGNDLigand Pharmaceuticals IncorporatedJun 2026$20K +0.0%+5.6%0.0%
OABIOmniAb, Inc.Mar 2026$14K +16.7%+5.3%0.0%
KPTIKaryopharm Therapeutics Inc.Mar 2026$14K +7.7%+5.3%0.0%
CDXSCodexis, Inc.Mar 2026$9K +12.5%+14.5%0.0%
CLYMClimb Bio, Inc.Mar 2026$5K -28.6%+18.6%0.0%
EVMNEvommune, Inc.Mar 2026$4K +300.0%—0.0%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$3K +0.0%—0.0%
Peer median (excluding EVMN) $14K+4.2%+7.1%0.0%

Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents29.02M16.25M44.06M
Short-term Investments50.06M55.79M105.14M
Net Receivables000
Inventory000
Other Current Assets948K1.95M4.28M
Total Current Assets80.03M73.99M153.48M
Property, Plant & Equipment (Net)1.97M1.8M2.46M
Goodwill000
Intangible Assets000
Long-term Investments208K208K68.9M
Tax Assets000
Other Non-current Assets44K61K101K
Total Non-current Assets2.22M2.07M71.47M
Total Assets82.25M76.06M224.95M
Account Payables1.76M8.26M7.76M
Short-term Debt769K1.02M589K
Tax Payables000
Deferred Revenue03M0
Other Current Liabilities1.89M12.07M4.63M
Total Current Liabilities6.86M27.98M17.91M
Long-term Debt149.37M191.78M0
Deferred Tax Liabilities000
Deferred Revenue (Non-current)3M00
Other Non-current Liabilities245K16K0
Total Non-current Liabilities153.11M192.31M1.47M
Total Liabilities159.96M220.29M19.38M
Common Stock1K1K3K
Retained Earnings(83.91M)(152.22M)(221.09M)
Accumulated OCI000
Other Stockholders Equity000
Minority Interest000
Total Equity(77.71M)(144.24M)205.57M
Total Debt150.63M193.31M2.06M
Net Debt121.61M177.06M(42M)

Evommune, Inc.

NYSE:EVMN

Intrinsic Alpha fair value

Locked

Current Price

$6.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.